Systemic treatments for thymic tumors: a narrative review.

Autor:	Zucali PA; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., De Vincenzo F; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Perrino M; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Digiacomo N; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Cordua N; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., D'Antonio F; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Borea F; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Santoro A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Jazyk:	angličtina
Zdroj:	Mediastinum (Hong Kong, China) [Mediastinum] 2021 Sep 25; Vol. 5, pp. 24. Date of Electronic Publication: 2021 Sep 25 (Print Publication: 2021).
DOI:	10.21037/med-21-11
Abstrakt:	Thymic epithelial tumours (TETs) are rare tumours originating from the thymus. Considering the rarity of this disease, the management of TETs is still challenging and difficult. In fact, all the worldwide clinical practice guidelines are based on data from retrospective analyses, prospective single arm trials or experts' opinions. The results of combined modality therapy (chemotherapy, surgery, radiotherapy) in thymic malignancies are reasonably good in less advanced cases whereas in case of advanced (unsuitable for surgery) or metastatic disease, a platinum-based chemotherapy is considered standard of care. Unfortunately, chemotherapy in the palliative setting has modest efficacy. Moreover, due to the lack of known oncogenic molecular alterations, no targeted therapy has been shown to be efficient for these tumours. In order to offer the best diagnostic and therapeutic tools, patients with TETs should be managed with a continuous and specific multidisciplinary expertise at any step of the disease, especially in the era of a novel coronavirus disease (COVID-19). Current evidences show that cancer patients might have more severe symptoms and poorer outcomes from COVID-19 infection than general population. With the exception of the patients carrying a Good's syndrome, there is no evidence that patients with TETs present a higher risk of infection compared with other cancer patients and their management should be the same. The aim of this review is to summarize the existing literature about systemic treatments for TETs in all clinical setting (local and locally advanced/metastatic disease) exploring how these therapeutic strategies have been managed in the COVID-19 era. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/med-21-11). The series “Changes in management of mediastinal tumours following the surge of COVID-19 pandemic” was commissioned by the editorial office without any funding or sponsorship. PAZ reports outside the submitted work personal fees for advisory role, speaker engagements and travel and accommodation expenses from Merck Sharp & Dohme (MSD), Astellas, Janssen, Sanofi, Ipsen, Pfizer, Novartis, Bristol Meyer Squibb, Amgen, Astrazeneca, Roche, and Bayer. AS reports outside the submitted work personal fees for consultant or advisory role for SArqule, Sanofi, BMS, Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp & Dohme (MSD). The authors have no other conflicts of interest to declare. (2021 Mediastinum. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu